An update from Mesoblast Limited ( (AU:MSB) ) is now available.
Mesoblast Limited announced that its product Ryoncil is now listed in all four major drug pricing compendia in the United States, following FDA approval of revised labeling. This development allows treatment centers to order Ryoncil kits tailored to patient dosages, potentially enhancing accessibility and standardizing pricing. The inclusion in these compendia is expected to bolster Mesoblast’s market positioning by facilitating easier access and ordering for healthcare providers, thereby potentially increasing the product’s adoption and utilization.
More about Mesoblast Limited
Mesoblast Limited is a global leader in developing allogeneic cellular medicines for treating severe inflammatory diseases. The company specializes in mesenchymal lineage cell therapy technology, which targets severe inflammation by releasing anti-inflammatory factors. Mesoblast’s flagship product, RYONCIL, is FDA-approved for treating steroid-refractory acute graft versus host disease in pediatric patients. The company is also developing therapies for other inflammatory conditions and has established commercial partnerships in Japan, Europe, and China.
YTD Price Performance: -37.73%
Average Trading Volume: 263,103
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $1.61B
See more data about MSB stock on TipRanks’ Stock Analysis page.